Abstract: Described herein are dosing regimens for the treatment of fungal infections such as onychomycosis using ravuconazole or a salt, solvate or prodrug thereof.

Abstract: Described herein are dosing regimens for the treatment of fungal infections such as onychomycosis using ravuconazole or a salt, solvate or prodrug thereof.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergies; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergies, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergies; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergies, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: This invention is directed to a gene sequence for secretory aspartic proteinase (SEQ ID No. 1) which is specific to pathogenic Candida yeast, to a highly sensitive method for detection of said gene in a sample solution and a kit used therefor.

Abstract: An antibiotic R106 represented by the general formula I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.-HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: There are provided R106 compounds represented by the following general formula (I): ##STR1## wherein: A.sub.1 is Phe, o-FPhe, m-FPhe, or Tyr;A.sub.2 is MePhe, o-FMePhe, m-FMePhe, MeTyr, Sar, MeSery, or .beta.-oxoMePhe;A.sub.3 is Pro, 4Hyp, or SPro;A.sub.4 is allo-Ile or Nle;A.sub.5 is Leu or Nva;A.sub.6 is .beta.-HOMeVal or Sar;excluding those wherein A.sub.1 is Phe and A.sub.2 is MePhe and A.sub.3 is Pro and A.sub.4 is allo-Ile and A.sub.5 is Leu and A.sub.6 is .beta.-HOMeVal (SEQ ID No. 4), which are useful as therapeutic agents for fungal infection.

Abstract: An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;X.sub.1 is MePhe, .beta.-HOMePhe or Phe;X.sub.2 is allo-Ile, Val or Leu;X.sub.3 is MeVal or Val;X.sub.4 is .beta.-HOMeVal, .gamma.-HOMeVal, MeVal, Val, N,.beta.-MeAsp, .beta.-HOMePhe, MePhe, MeDH.sub.2,3 Val or MeDH.sub.3,4 Valis produced by a process which comprises culturing a strain of the genus Aureobasidium that is capable of producing the said antibiotic R106 and collecting the said antibiotic from the fermentation broth. The antibiotic R106 compounds are useful in the treatment of fungal infection.

Abstract: Method for the treatment of systemic mycosis of mammals comprises administering (S)-2-amino-5-hydroxy-4-oxopentanoicacid in a therapeutically effective amount to said mammals suffering from mycosis, typically candidosis.